| | | | | | Product | Package Size | EFP | CP | SB | DC | Composition | Registr. Holder | Category | | | | |
|---|
|
| | | IP | CI | | Ebvallo | | PR | PR | k.A. | | | Pierre Fabre Pharma SA | A | FB | | G |  |
| L | | IP | | | Vegzelma 100 mg/4 ml | | 257.57 | 296.55 | 10 % | | Concentrate for infusion: Bevacizumabum 100mg / 4ml | iQone Healthcare
Switzerland SA | A / SL | FB | | G | |
| L | | IP | | | Vegzelma 400 mg/16 ml | | 962.84 | 1063.55 | 10 % | | Concentrate for infusion: Bevacizumabum 400mg / 16ml | iQone Healthcare
Switzerland SA | A / SL | FB | | G | |
| L | | IP | | PP | Herceptin subkutan
600mg/5ml | | 1484.04 | 1630.40 | 10 % | | Lösung zur subkutanen Injektion: Trastuzumabum 600mg / 5ml | Roche Pharma
(Schweiz) AG | A / SL | FB | | G | |
| L | | IP | | | Ogivri 150 mg | | 456.84 | 513.25 | 10 % | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trastuzumabum 150 mg | Medius AG | A / SL | FB | | G | |
| | | IP | CI | | Bilaxten 6 mg / ml | 5 ml | PR | PR | k.A. | | Eye drops: Bilastinum 6 mg/ml | A. Menarini GmbH | B | FB | | G | |
| | | IP | CI | | Regaine 2 % | 60 ml | PR | PR | k.A. | | Solution: Minoxidilum 20 mg/ml | JNTL Consumer Health II
(Switzerland) GmbH | D / LPPV | FB | | G | |
| | | IP | CI | | Regaine 2 % | 3 x 60 ml | PR | PR | k.A. | | Solution: Minoxidilum 20 mg/ml | JNTL Consumer Health II
(Switzerland) GmbH | D / LPPV | FB | | G | |
| | | IP | CI | | Regaine 5 % | 60 ml | PR | PR | k.A. | | Solution: Minoxidilum 50 mg/ml | JNTL Consumer Health II
(Switzerland) GmbH | D / LPPV | FB | | G | |
| | | IP | CI | | Regaine 5 % | 3 x 60 ml | PR | PR | k.A. | | Solution: Minoxidilum 50 mg/ml | JNTL Consumer Health II
(Switzerland) GmbH | D / LPPV | FB | | G | |
| | | IP | | | Mylotarg 5 mg | | PR | PR | k.A. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Gemtuzumabum Ozogamicinum 5 mg | Pfizer AG | A | FB | | G | |
|
| | | IP | CI | | Activelle | 28 Tablet(s) | 8.38 | 25.55 | 10 % | | Coated tablets: 2 Active Agents | Novo Nordisk Pharma AG | B / SL | FB | | G | |
| | | IP | CI | | Kliogest N | 28 Tablet(s) | 8.20 | 25.35 | 10 % | | Coated tablets: 2 Active Agents | Novo Nordisk Pharma AG | B / SL | FB | | G | |
| | | IP | CI | | Systen Conti | 8 plaster(s) | 12.04 | 29.50 | 10 % | | patch transdermique: 2 Active Agents | Labatec Pharma SA | B / SL | FB | | G | |
| | | IP | CI | | Systen Conti | 24 plaster(s) | 31.28 | 50.45 | 10 % | | patch transdermique: 2 Active Agents | Labatec Pharma SA | B / SL | FB | | G | |
| | | IP | CI | | Systen Sequi | 8 plaster(s) | 7.66 | 17.55 | 10 % | | patch transdermique (emballage combiné): Estradiolum 3.1 mg
patch transdermique (emballage combiné): 2 Active Agents | Labatec Pharma SA | B / SL | FB | | G | |
| | | IP | | | Estalis 50/140 | 8 plaster(s) | 10.55 | 27.90 | k.A. | | Transdermal patch: 2 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
| | | IP | | | Estalis 50/140 | 24 plaster(s) | 27.46 | 46.30 | k.A. | | Transdermal patch: 2 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
| | | IP | | | Estalis 50/250 | 8 plaster(s) | 11.63 | 29.05 | k.A. | | Transdermal patch: 2 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
| | | IP | | | Estalis 50/250 | 24 plaster(s) | 32.44 | 51.70 | k.A. | | Transdermal patch: 2 Active Agents | Sandoz
Pharmaceuticals AG | B | FB | | G | |
